{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:22:06Z","timestamp":1791602526648,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Participation Program at the Center for Drug Evaluation and Research"},{"DOI":"10.13039\/100006229","name":"Oak Ridge Institute for Science and Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"US Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009210","name":"US Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.vascn.2020.106890","type":"journal-article","created":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T01:35:39Z","timestamp":1592703339000},"page":"106890","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["A general procedure to select calibration drugs for lab-specific validation and calibration of proarrhythmia risk prediction models: An illustrative example using the CiPA model"],"prefix":"10.1016","volume":"105","author":[{"given":"Xiaomei","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Samieegohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy W.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phu","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiansong","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Stoelzle-Feix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Brinkwirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giustina","family":"Rotordam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Friis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Rapedius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom A.","family":"Goetze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Strassmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Okeyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Kuryshev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2020.106890_bb0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.vascn.2016.12.003","article-title":"A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes","volume":"84","author":"Ando","year":"2017","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2020.106890_bb0010","author":"Biomarker Qualification: Evidentiary Framework"},{"issue":"13","key":"10.1016\/j.vascn.2020.106890_bb0015","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.celrep.2018.08.079","article-title":"International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment","volume":"24","author":"Blinova","year":"2018","journal-title":"Cell Reports"},{"key":"10.1016\/j.vascn.2020.106890_bb0020","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fchem.2018.00504","article-title":"Traditional calibration methods in atomic spectrometry and new calibration strategies for inductively coupled plasma mass spectrometry","volume":"6","author":"Carter","year":"2018","journal-title":"Frontiers in Chemistry"},{"issue":"3","key":"10.1016\/j.vascn.2020.106890_bb0025","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/sj.bjp.0706070","article-title":"Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres","volume":"144","author":"Champeroux","year":"2005","journal-title":"British Journal of Pharmacology"},{"issue":"917","key":"10.1016\/j.vascn.2020.106890_bb0030","article-title":"Uncertainty quantification reveals the importance of data variability and experimental design considerations for in silico proarrhythmia risk assessment","volume":"8","author":"Chang","year":"2017","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.vascn.2020.106890_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2016.06.002","article-title":"The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - update on progress","author":"Colatsky","year":"2016","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2020.106890_bb0040","series-title":"Assessing the reliability of complex models: Mathematical and statistical foundations of verification, validation, and uncertainty quantification","author":"Council, N. R","year":"2012"},{"key":"10.1016\/j.vascn.2020.106890_bb0045","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3389\/fphys.2017.00616","article-title":"Optimization of an in silico cardiac cell model for proarrhythmia risk assessment","volume":"8","author":"Dutta","year":"2017","journal-title":"Frontiers in Physiology"},{"issue":"1","key":"10.1016\/j.vascn.2020.106890_bb0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.vascn.2013.04.007","article-title":"Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment","volume":"68","author":"Elkins","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2020.106890_bb0055","author":"Gintant"},{"issue":"7","key":"10.1016\/j.vascn.2020.106890_bb0060","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrd.2015.34","article-title":"Evolution of strategies to improve preclinical cardiac safety testing","volume":"15","author":"Gintant","year":"2016","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"4","key":"10.1016\/j.vascn.2020.106890_bb0065","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jphs.2018.10.010","article-title":"Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update","volume":"138","author":"Kanda","year":"2018","journal-title":"Journal of Pharmacological Sciences"},{"key":"10.1016\/j.vascn.2020.106890_bb0070","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/srep02100","article-title":"MICE models: Superior to the HERG model in predicting Torsade de Pointes","volume":"3","author":"Kramer","year":"2013","journal-title":"Scientific Reports"},{"key":"10.1016\/j.vascn.2020.106890_bb0075","doi-asserted-by":"crossref","first-page":"106654","DOI":"10.1016\/j.vascn.2019.106654","article-title":"Improving prediction of torsadogenic risk in the CiPA in silico model by appropriately accounting for clinical exposure","volume":"101","author":"Leishman","year":"2020","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2020.106890_bb0080","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004628","article-title":"Improving the in silico assessment of proarrhythmia risk by combining hERG (human ether-a-go-go-related gene) channel-drug binding kinetics and multichannel pharmacology","volume":"10","author":"Li","year":"2017","journal-title":"Circulation. Arrhythmia and Electrophysiology"},{"key":"10.1016\/j.vascn.2020.106890_bb0085","article-title":"Quantitative systems pharmacology models for a new international cardiac safety regulatory paradigm: An overview of the comprehensive in vitro proarrhythmia assay in silico modeling approach","author":"Li","year":"2019","journal-title":"CPT: Pharmacometrics & Systems Pharmacology."},{"key":"10.1016\/j.vascn.2020.106890_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1184","article-title":"General principles for the validation of proarrhythmia risk prediction models: An extension of the cipa in silico strategy","author":"Li","year":"2019","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.vascn.2020.106890_bb0095","article-title":"Assessment of an in silico mechanistic model for proarrhythmia risk prediction under the CiPA initiative","author":"Li","year":"2018","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"8","key":"10.1016\/j.vascn.2020.106890_bb0100","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.hrthm.2006.04.021","article-title":"Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias","volume":"3","author":"Liu","year":"2006","journal-title":"Heart Rhythm"},{"issue":"2","key":"10.1016\/j.vascn.2020.106890_bb0105","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.vascn.2010.02.007","article-title":"Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide","volume":"61","author":"Milnes","year":"2010","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"3","key":"10.1016\/j.vascn.2020.106890_bb0110","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.503","article-title":"Complexity vs. simplicity: The winner is?","volume":"101","author":"Mistry","year":"2017","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.vascn.2020.106890_bb0115","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.4352","article-title":"Complex versus simple models: Ion-channel cardiac toxicity prediction","volume":"6","author":"Mistry","year":"2018","journal-title":"PeerJ"},{"key":"10.1016\/j.vascn.2020.106890_bb0120","author":"Mistry"},{"key":"10.1016\/j.vascn.2020.106890_bb0125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fphar.2015.00059","article-title":"A new classifier-based strategy for in-silico ion-channel cardiac drug safety assessment","volume":"6","author":"Mistry","year":"2015","journal-title":"Frontiers in Pharmacology"},{"issue":"3","key":"10.1016\/j.vascn.2020.106890_bb0130","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1373\/49.3.425","article-title":"PCR-based calibration curves for studies of quantitative gene expression in human monocytes: Development and evaluation","volume":"49","author":"Ovstebo","year":"2003","journal-title":"Clinical Chemistry"},{"key":"10.1016\/j.vascn.2020.106890_bb0135","author":"Questions & Answers: Clinical and Non-clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential (Concept Paper)"},{"key":"10.1016\/j.vascn.2020.106890_bb0140","article-title":"A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm","volume":"114961","author":"Ridder","year":"2020","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.vascn.2020.106890_bb0145","author":"Strauss"},{"key":"10.1016\/j.vascn.2020.106890_bb0150","series-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use","author":"The Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs E14","year":"2005"},{"key":"10.1016\/j.vascn.2020.106890_bb0155","series-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use","author":"The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals S7B","year":"2005"},{"issue":"1","key":"10.1016\/j.vascn.2020.106890_bb0160","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cpt.896","article-title":"Mechanistic model-informed Proarrhythmic risk assessment of drugs: Review of the \u201cCiPA\u201d initiative and design of a prospective clinical validation study","volume":"103","author":"Vicente","year":"2018","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1016\/j.vascn.2020.106890_bb0165","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/15376510902777194","article-title":"hERG in vitro interchange factors\u2014Development and verification","volume":"19","author":"Wisniowska","year":"2009","journal-title":"Toxicology Mechanisms and Methods"},{"issue":"1","key":"10.1016\/j.vascn.2020.106890_bb0170","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0006-3495(98)77782-3","article-title":"Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature","volume":"74","author":"Zhou","year":"1998","journal-title":"Biophysical Journal"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871920302197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871920302197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:06:04Z","timestamp":1761005164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871920302197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":34,"alternative-id":["S1056871920302197"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2020.106890","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A general procedure to select calibration drugs for lab-specific validation and calibration of proarrhythmia risk prediction models: An illustrative example using the CiPA model","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2020.106890","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106890"}}